Bioavailability, safety and immunogenicity of biosimilar infliximab (BOW015) compared to reference infliximab.
暂无分享,去创建一个
J. Kay | M. Wyand | C. Lassen | J. Willers | L. Shneyer | J. Lambert | E. Thomson | A. Knight
暂无分享,去创建一个
J. Kay | M. Wyand | C. Lassen | J. Willers | L. Shneyer | J. Lambert | E. Thomson | A. Knight